Phase 3 Readout
BBIO: Phase 3 Topline: An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Sympto
May 15, 2028 · acoramidis. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- May 15, 2028
- Company
- BridgeBio Pharma, Inc. (BBIO)
- Drug
- acoramidis
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Sympto
- Drug
- acoramidis